Evidence map›Paper›PMID 36558473›Full record

ArticleNutrients2022

Statin-Induced Geranylgeranyl Pyrophosphate Depletion Promotes PCSK9-Dependent Adipose Insulin Resistance.

Xin Shu, Jiaqi Wu, Tao Zhang, Xiaoyu Ma, Zuoqin Du, Jin Xu, Jingcan You, Liqun Wang, Ni Chen, Mao Luo and 1 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xin ShuDrug Discovery Research Center, Southwest Medical University, Luzhou 646000, China.
Jiaqi WuDrug Discovery Research Center, Southwest Medical University, Luzhou 646000, China.
Tao ZhangDrug Discovery Research Center, Southwest Medical University, Luzhou 646000, China.
Xiaoyu MaDrug Discovery Research Center, Southwest Medical University, Luzhou 646000, China.
Zuoqin DuDrug Discovery Research Center, Southwest Medical University, Luzhou 646000, China.
Jin XuDrug Discovery Research Center, Southwest Medical University, Luzhou 646000, China.
Jingcan YouDrug Discovery Research Center, Southwest Medical University, Luzhou 646000, China.
Liqun WangDrug Discovery Research Center, Southwest Medical University, Luzhou 646000, China.
Ni ChenDrug Discovery Research Center, Southwest Medical University, Luzhou 646000, China.
Mao LuoDrug Discovery Research Center, Southwest Medical University, Luzhou 646000, China.ORCID 0000-0002-9076-7875
Jianbo WuDrug Discovery Research Center, Southwest Medical University, Luzhou 646000, China.
Southwest Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statin treatment is accepted to prevent adverse cardiovascular events. However, statin therapy has been reported to be dose-dependently associated with increased risk for new-onset type 2 diabetes mellitus (T2DM). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is expressed in adipose tissue and is positively correlated with lipid metabolism. It is, however, unknown if PCSK9 participates in adipocyte insulin resistance occurring as a result of statin use. Our goal was to use an in vitro adipose tissue explant approach to support the hypothesis that PCSK9 regulates statin-induced new-onset T2DM. Studies were performed using Pcsk

Indexed as

Diabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistanceAnimalsAtorvastatinInsulinMiceObesityPolyisoprenyl PhosphatesProprotein Convertase 9Atorvastatingeranylgeranyl pyrophosphateHydroxymethylglutaryl-CoA Reductase InhibitorsInsulinPcsk9 protein, mousePolyisoprenyl PhosphatesProprotein Convertase 9adipose tissueinsulin resistanceobesityPCSK9statin

Identifiers

PMID36558473
PMCPMC9853319
OpenAlexW4311793718

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.